| Age group | |||
---|---|---|---|---|
Oxidative markers | 35-49 years | > 50 years | ||
 | Placebo | TRF | Placebo | TRF |
Protein carbonyl (nmol/mg) | Â | Â | Â | Â |
   Baseline (0 month) | 0.54 ± 0.08 | 0.58 ± 0.08 | 0.50 ± 0.06 | 0.63 ± 0.03 |
   3 months | 0.56 ± 0.13 | 0.54 ± 0.05 | 0.48 ± 0.05 | 0.52 ± 0.06 |
   6 months | 0.60 ± 0.08 | 0.51 ± 0.06 | 0.47 ± 0.04 | 0.40 ± 0.03** |
Advanced glycosylation end-product (units/ml) | Â | Â | Â | Â |
   Baseline (0 month) | 2.39 ± 0.15 | 2.10 ± 0.22 | 2.34 ± 0.22 | 2.73 ± 0.26 |
   3 months | 2.01 ± 0.18 | 2.38 ± 0.21 | 2.30 ± 0.26 | 2.24 ± 0.35 |
   6 months | 2.12 ± 0.22 | 2.02 ± 0.17 | 1.98 ± 0.25 | 1.71 ± 0.24* |
Malondialdehyde (nmol/ml) | Â | Â | Â | Â |
   Baseline (0 month) | 4.25 ± 0.30 | 3.45 ± 0.37 | 4.18 ± 0.23 | 4.71 ± 0.41 |
   3 months | 4.82 ± 0.34 | 3.95 ± 0.39 | 3.22 ± 0.22 | 3.86 ± 0.34 |
   6 months | 3.95 ± 0.31 | 4.48 ± 0.27 | 3.87 ± 0.36 | 3.87 ± 0.32 |